EVERSANA partners with Innovacell to launch ICEF15 cell therapy in the United States

EVERSANA, a global commercialization services provider for the life‑sciences sector, has been chosen by Tokyo‑based Innovacell Inc. as its exclusive partner to bring ICEF15, a novel regenerative‑medicine cell therapy for urgent fecal incontinence, to the U.S. market. The partnership will give Innovacell access to EVERSANA’s end‑to‑end platform, covering pre‑launch strategy, market access, patient engagement, data analytics, field deployment and distribution. "Cell and gene therapies require new ways of thinking to bring novel medicines to market," said Mark Thierer, CEO of EVERSANA. Innovacell’s Co‑CEO Jason Sieger added that EVERSANA’s expertise will help build a strong launch foundation.

In a separate announcement, EVERSANA is hiring a Medical Affairs Operations Coordinator. The role will support the Global Medical Affairs team by managing recruitment, headcount forecasting, project‑trackers, client coordination and internal SOPs, primarily across U.S. time zones.